“we we expect to run, two studies for approval, one biomarker based and the other outcomes based? And so there will be an outcome study. There'll need to be. I I don't think the outcomes data will, be an impediment for for Lufendra's, initial launch.”
→ Read the source episode
Coursera initiates and completes biomarker-based and outcomes-based clinical studies for their siRNA program
Greg Savonovich predicts the biotech sector will continue to rally through the rest of 2026
Yaron Werber expects Forte will report phase 2b celiac and phase 1b alopecia areata data by end of 2026
Matt Klein's company will launch brepacitinib within the next two to two and a half months
Yaron Werber predicts Forte's phase 2b celiac disease study will be positive
Yaron Werber predicts Gilead's Anido Cell (anti-BCMA CAR-T) will receive FDA approval in December 2026
John predicts France will win the third-place match and Argentina will beat France 3-2 in the World Cup final on Sunday
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.